retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial First-in-Class 'Triple-G'! Retatrutide, a first-in-class GIP, & hormone receptor drug leads to nearly 29% weight loss in first pivotal test! Eli Lilly announced positive topline results from the Retatrutide 40mg | Triple GIP/GLP-1/Glucagon
Description
We work hard to keep pricing current, but you may find a better offer

This alarming trend has led to a heightened demand for effective pharmacological interventions, particularly GLP-1 receptor agonists, which have demonstrated efficacy in weight loss and glycemic control

Lets discuss! (Source: @ Curios VC) #obesity #glp #biotech #biopharma Informative

However, most formularies cover both Wegovy and Zepbound, so rebates are currently not driving competition, but rather stifling innovative management strategies
